VanEck Biotech ETF (NASDAQ:BBH – Get Free Report) reached a new 52-week high during trading on Thursday. The company traded as high as $269.90 and last traded at $260.3710, with a volume of 1,235 shares trading hands. The stock had previously closed at $261.63.
VanEck Biotech ETF Trading Down 0.8%
The company’s fifty day moving average price is $241.94 and its two-hundred day moving average price is $207.76.
Hedge Funds Weigh In On VanEck Biotech ETF
Several large investors have recently added to or reduced their stakes in the company. Kestra Advisory Services LLC lifted its stake in VanEck Biotech ETF by 3.0% during the first quarter. Kestra Advisory Services LLC now owns 3,405 shares of the company’s stock worth $640,000 after purchasing an additional 98 shares during the last quarter. Janney Montgomery Scott LLC grew its position in VanEck Biotech ETF by 3.4% during the 1st quarter. Janney Montgomery Scott LLC now owns 3,040 shares of the company’s stock worth $572,000 after purchasing an additional 100 shares in the last quarter. Coastline Trust Co acquired a new stake in VanEck Biotech ETF during the 3rd quarter valued at $46,000. CoreCap Advisors LLC acquired a new position in VanEck Biotech ETF in the 3rd quarter valued at approximately $46,000. Finally, Caldwell Trust Co acquired a new stake in shares of VanEck Biotech ETF during the 3rd quarter worth approximately $47,000. 32.05% of the stock is currently owned by institutional investors.
VanEck Biotech ETF Company Profile
The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.
Further Reading
- Five stocks we like better than VanEck Biotech ETF
- Matador Resources Insider Buying and the Case for a Dividend Stock Rebound
- Datadog’s Post-Earnings Sell-Off: A Buying Opportunity in Plain Sight?
- How Much of Tesla’s Robotaxi Future Is Already Priced In?
- 3 AI Infrastructure Plays Beyond Chipmakers
Receive News & Ratings for VanEck Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
